Delving into the Latest Updates on Shanghai Junpaiyingshi Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PARP1 x PARP2	1

I期：剂量递增阶段-评价特瑞普利单抗联合 Senaparib在晚期肿瘤患者中的安全性和耐受性；确定特瑞普利单抗联合 Senaparib在晚期肿瘤患者中的MTD和RP2D Ib期：队列扩展阶段-初步评价特瑞普利单抗联合 Senaparib在特定晚期肿瘤患者中的有效性及安全性

[Translation]

Phase I: Dose escalation phase - evaluate the safety and tolerability of toripalimab combined with senaparib in patients with advanced tumors; determine the MTD and RP2D of toripalimab combined with senaparib in patients with advanced tumors Phase Ib: Cohort expansion phase - preliminary evaluation of the efficacy and safety of toripalimab combined with senaparib in specific patients with advanced tumors

Start Date-

Sponsor / Collaborator

Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

NCT05824455 / TerminatedPhase 1/2

An Open, Multicenter, Phase Ib/II Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors

The Phase Ib study was designed to evaluate the safety of JS109 in combination with irinotecan in the treatment of advanced solid tumors and to determine the Phase II recommended dose (RP2D). The Phase II study was designed to evaluate the efficacy and safety of the combination regimen in patients with extensive small-cell lung cancer (SCLC) that failed first-line platinum-containing regimen.

Start Date23 Mar 2023

Sponsor / Collaborator

Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

CTR20221169 / CompletedPhase 2

一项在晚期实体瘤和小细胞肺癌患者中评估IMP4297与替莫唑胺联用的安全性、耐受性、药代动力学及抗肿瘤活性的Ⅰb/Ⅱ期、开放性、多中心、剂量递增和扩展研究

[Translation] A Phase Ib/II, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of IMP4297 in combination with temozolomide in patients with advanced solid tumors and small cell lung cancer

在晚期实体瘤和在接受1L含铂方案治疗后出现疾病进展的ES-SCLC患者中评估PARP抑制剂IMP4297与替莫唑胺联用的安全性、耐受性、PK特性及抗肿瘤活性。

[Translation]

To evaluate the safety, tolerability, PK properties, and antitumor activity of the PARP inhibitor IMP4297 in combination with temozolomide in patients with advanced solid tumors and ES-SCLC with disease progression after 1L platinum-containing therapy.

Start Date06 Jun 2022

Sponsor / Collaborator

Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

100 Clinical Results associated with Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Junpaiyingshi Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data